Skip to main content
    O

    Opko Health Inc (OPK)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.62
    -0.06 (-3.57%)

    Market Cap: $1.25B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Opko Health Inc (OPK) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Opko Health (OPK) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Opko Health reported EPS of -$0.05, above the -$0.07 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -4.90%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.11 - -$0.05
    7 analysts
    Revenue Consensus
    $81.64M
    Range$64.68M - $154.56M
    7 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.11
    Range-$0.11 - -$0.11
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.08-37.5%
    60d ago-$0.08-37.5%
    30d ago-$0.08-37.5%
    7d ago-$0.08-46.7%
    Current-$0.11
    Revenue Consensus
    $80.28M
    Range$59.30M - $135.80M
    4 analysts

    Next Report

    OPK has an expected report date of Feb 24, 2027.

    OPK Earnings Call

    The latest OPK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OPK beat 19, missed 13 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $65.41M, up 15.9% from $56.42M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.07-$0.08 - -$0.05+28.57%Beat-266.7%31 up, 0 downNov 4, 2026$65.41M
    Jun 30, 2026-$0.01-$0.08N/A+87.50%BeatN/A10 up, 0 downJul 27, 2026$163.58M
    Mar 31, 2026-$0.07-$0.07-$0.08 - -$0.050.00%In lineN/A62 up, 2 downApr 28, 2026$124.20M
    Dec 31, 2025-$0.04-$0.07-$0.07 - -$0.07+42.86%Beat-500.0%11 up, 0 downFeb 26, 2026$148.45M
    Sep 30, 2025$0.03-$0.04-$0.11 - $0.03+175.00%Beat0.0%62 up, 2 downOct 29, 2025$56.42M
    Jun 30, 2025-$0.08-$0.10-$0.10 - -$0.10+20.00%BeatN/A10 up, 0 downJul 31, 2025$156.81M
    Mar 31, 2025-$0.09-$0.11-$0.11 - -$0.11+18.18%BeatN/A10 up, 0 downApr 30, 2025$149.95M
    Dec 31, 2024$0.01-$0.10N/A+110.00%BeatN/AN/A0 up, 0 downFeb 27, 2025$183.64M
    Sep 30, 2024$0.03-$0.09-$0.11 - -$0.07+133.33%BeatN/A60 up, 0 downNov 7, 2024$173.63M
    Jun 30, 2024-$0.01-$0.09-$0.12 - -$0.07+88.89%BeatN/A60 up, 0 downAug 7, 2024$182.19M
    Mar 31, 2024-$0.12-$0.09-$0.14 - -$0.06-33.33%MissN/A60 up, 0 downMay 7, 2024$173.69M
    Dec 31, 2023-$0.09-$0.09-$0.10 - -$0.080.00%In lineN/A50 up, 0 downFeb 27, 2024$181.91M
    Sep 30, 2023-$0.11-$0.10-$0.16 - -$0.08-10.00%MissN/A60 up, 0 downNov 6, 2023$178.59M
    Jun 30, 2023-$0.03-$0.07-$0.13 - $0.02+57.14%BeatN/A60 up, 0 downAug 3, 2023$265.42M
    Mar 31, 2023-$0.02-$0.08-$0.14 - -$0.02+75.00%BeatN/A60 up, 0 downMay 3, 2023$237.58M
    Dec 31, 2022-$0.11-$0.11-$0.16 - -$0.080.00%In lineN/A60 up, 0 downFeb 23, 2023$185.34M
    Sep 30, 2022-$0.11-$0.08-$0.13 - -$0.06-37.50%Miss-375.0%50 up, 0 downNov 8, 2022$179.74M
    Jun 30, 2022-$0.14$0.03-$0.06 - $0.07-566.67%MissN/A50 up, 0 downAug 4, 2022$309.89M
    Mar 31, 2022-$0.08-$0.06-$0.11 - -$0.01-33.33%Miss-260.0%50 up, 0 downMay 9, 2022$329.22M
    Dec 31, 2021-$0.11-$0.02-$0.03 - -$0.01-450.00%Miss-320.0%50 up, 0 downFeb 24, 2022$401.33M
    Sep 30, 2021$0.04-$0.01-$0.03 - $0.01+500.00%Beat0.0%5N/AOct 28, 2021$385.81M
    Jun 30, 2021-$0.03$0.02$0.00 - $0.03-250.00%Miss-160.0%5N/AJul 29, 2021$442.41M
    Mar 31, 2021$0.05$0.05$0.04 - $0.060.00%In lineN/A5N/AApr 28, 2021$545.16M
    Dec 31, 2020$0.05$0.04$0.02 - $0.07+25.00%BeatN/A5N/AFeb 18, 2021$494.68M
    Sep 30, 2020$0.04$0.04$0.04 - $0.060.00%In lineN/A5N/AOct 29, 2020$428.06M
    Jun 30, 2020$0.05-$0.07-$0.10 - -$0.02+171.43%BeatN/A5N/AJul 30, 2020$301.21M
    Mar 31, 2020-$0.09-$0.09-$0.09 - -$0.080.00%In lineN/A4N/AMay 6, 2020$211.47M
    Dec 31, 2019-$0.18-$0.09-$0.10 - -$0.08-100.00%MissN/A4N/AFeb 26, 2020$224.34M
    Sep 30, 2019-$0.11-$0.09-$0.10 - -$0.08-22.22%MissN/A3N/ANov 5, 2019$228.77M
    Jun 30, 2019-$0.11-$0.11-$0.12 - -$0.100.00%In lineN/A3N/AAug 7, 2019$226.37M
    Mar 31, 2019-$0.13-$0.11-$0.13 - -$0.03-18.18%MissN/A3N/AMay 7, 2019$222.45M
    Dec 31, 2018-$0.09-$0.09-$0.10 - -$0.070.00%In lineN/A3N/AFeb 27, 2019$221.85M
    Sep 30, 2018-$0.05-$0.06-$0.11 - -$0.05+16.67%BeatN/A5N/ANov 9, 2018$249.81M
    Jun 30, 2018-$0.03-$0.07-$0.10 - -$0.02+57.14%BeatN/A6N/AAug 7, 2018$263.69M
    Mar 31, 2018-$0.08-$0.13-$0.16 - -$0.10+38.46%BeatN/A5N/AMay 8, 2018$254.91M
    Dec 31, 2017-$0.32-$0.08-$0.10 - -$0.05-300.00%MissN/A6N/AMar 1, 2018$943.69M
    Sep 30, 2017-$0.08-$0.05-$0.07 - -$0.03-60.00%MissN/A6N/ANov 8, 2017$246.04M
    Jun 30, 2017-$0.03-$0.05-$0.07 - -$0.03+40.00%BeatN/A5N/AAug 8, 2017$292.60M
    Mar 31, 2017-$0.06-$0.04N/A-50.00%MissN/AN/AN/AMay 9, 2017$266.38M
    Dec 31, 2016-$0.02-$0.04N/A+50.00%Beat-789.7%N/AN/AMar 1, 2017$171.32M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.18, after -$0.09 the year before. It was -$0.09 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.18N/A
    Dec 31, 2024-$0.09N/A
    Dec 31, 2023-$0.25N/A
    Dec 31, 2022-$0.44N/A
    Dec 31, 2021-$0.05-200.0%
    Dec 31, 2020$0.05N/A
    Dec 31, 2019-$0.53N/A
    Dec 31, 2018-$0.25N/A
    Dec 31, 2017-$0.49N/A
    Dec 31, 2016-$0.09N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,41810
    2026Q2Jun 30, 20266,15412
    2025Q4Dec 31, 20255,40111
    2025Q3Sep 30, 20256,37912
    2025Q2Jun 30, 20255,53810
    2025Q1Mar 31, 20255,38412
    2024Q4Dec 31, 20244,93011
    2024Q3Sep 30, 20245,54010

    2026Q3 Earnings Call

    Opening remarks

    Vivian Cervantes Investor Relations, Alliance Advisors Thank you, operator. Good afternoon, everyone. Thank you for joining us on today's call to discuss OPKO Health's financial results for the third quarter of 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and, as such, are subject to risks and uncertainties that could materially affect the company's results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 4, 2026. Except as required by law, OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Regarding the format of today's call, Dr. Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, President and Vice Chairman, will then review OPKO's pipeline and business. After that, Adam Logal, OPKO's Chief Financial Officer, will review the new LabCorp transaction, the company's third-quarter financial results, and its outlook. We will then open the line for questions. I'd now like to turn the call over to Dr. Frost.

    Phillip Frost Chairman and CEO Good afternoon, and thank you for joining us today. The LabCorp transaction marks a defining moment for OPKO. Once closed, it will complete our exit from clinical laboratory services, sharpen our focus, and allow our management attention, our people, and our capital to focus on biotech innovation and our global products business. Adam will provide the transaction and financial details later. This reflects the approach we have applied throughout OPKO's history: build differentiated businesses and assets, validate their value, monetize them at the right time, and redeploy capital into our highest-return opportunities. Going forward, OPKO is centered on two continuing businesses. Innovative Biotech brings together ModeX and OPKO Biologics, with a broad portfolio across oncology, immunology, infectious disease, and endocrinology. Global Products includes Rayaldee and our international pharmaceutical operations, with established commercial capabilities and recurring cash flow. The third quarter was one of steady execution across our pipeline. ModeX expanded its clinical activity, completed enrollment in the planned Phase I cohorts for MDX-2301, and continued advancing our differentiated in vivo CAR-T platform toward the clinic. Elias will discuss that progress. The collaborations with Merck, Regeneron, Entera Bio, and BARDA continue to add scientific capability, external validation, and nondilutive support, while NGENLA, Rayaldee, and our international operations contribute to the strength of the business.

    Frequently Asked Questions About OPK

    When is Opko Health's next earnings date?

    Opko Health's next earnings report is expected for Feb 24, 2027.

    Did OPK beat earnings estimates last quarter?

    Yes. Opko Health reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.07 estimate, a 28.57% surprise.

    What EPS do analysts expect from OPK next quarter?

    The consensus EPS estimate for Opko Health for the quarter ending Dec 31, 2026 is -$0.07 from 7 analysts, with estimates from -$0.11 to -$0.05.

    How often does OPK beat earnings estimates?

    Opko Health beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +60.26%.